Clinical and laboratory data of CLL patients according to BCL2 gene polymorphism -938C>A
| . | Whole group . | AA . | AC . | CC . | P . |
|---|---|---|---|---|---|
| No. of cases | 276 | 97 | 127 | 52 | |
| Mean age at diagnosis (N = 276), (range) | 64 (30-97) | 63 (34-85) | 65 (35-89) | 64 (39-97) | .6 |
| Sex (N = 272) | |||||
| Male | 179 (66%) | 59 (61%) | 86 (69%) | 34 (67%) | .5 |
| Female | 93 (34%) | 37 (39%) | 39 (31%) | 17 (33%) | — |
| Male/female ratio | 1.9:1 | 1.6:1 | 2.2:1 | 2.0:1 | — |
| Stage (N = 251) | |||||
| AO | 121 (48%) | 48 (55%) | 54 (45%) | 19 (44%) | .1 |
| A | 67 (27%) | 25 (28%) | 31 (26%) | 11 (26%) | — |
| B | 51 (20%) | 14 (16%) | 25 (21%) | 12 (28%) | — |
| C | 12 (5%) | 1 (1%) | 10 (8%) | 1 (2%) | — |
| Genomic aberrations (N = 152) | |||||
| Deletion 13q14 | 50 | 15 | 25 | 10 | — |
| Trisomy 12 | 20 | 6 | 12 | 2 | — |
| Deletion 11q23 | 18 | 5 | 9 | 4 | — |
| Deletion 17p13 | 1 | 1 | 0 | 0 | — |
| t(14;18)/IGH-BCL2 fusion * | 5 | 2 | 1 | 1 | — |
| IGHV mutational status (N = 225) | |||||
| Mutated (<98% homology to germline) | 155 (69%) | 54 (71%) | 76 (70%) | 25 (63%) | .4 |
| Unmutated | 66 (29%) | 19 (25%) | 32 (29%) | 15 (37%) | — |
| Mean WCC at diagnosis (N = 249), (range) | 41 (4.3-554) | 37.9 (5.5-234) | 51.4 (4.5-554) | 33.8 (4.3-254) | .3 |
| Treatment status (N = 250) | |||||
| Treated | 98 (39%) | 35 (40%) | 46 (38%) | 17 (40%) | .9 |
| Untreated | 152 (61%) | 52 (60%) | 74 (62%) | 26 (60%) | — |
| Mean time from diagnosis to first treatment (N = 98), mo | 28.5 | 28 | 25.6 | 32 | .3 |
| Survival (N = 258) | |||||
| Dead | 34 (13%) | 14 (16%) | 16 (13%) | 4 (9%) | .5 |
| Alive | 224 (87%) | 76 (84%) | 106 (87%) | 42 (91%) | — |
| BCL2 expression (N = 100) | |||||
| High (BCL2:actin ratio/SC-1>0.48) | 80 (80%) | 31 (89%) | 32 (73%) | 17 (81%) | .7 |
| Low (BCL2:actin ratio/SC-1<0.48) | 20 (20%) | 4 (11%) | 12 (27%) | 4 (19%) | — |
| . | Whole group . | AA . | AC . | CC . | P . |
|---|---|---|---|---|---|
| No. of cases | 276 | 97 | 127 | 52 | |
| Mean age at diagnosis (N = 276), (range) | 64 (30-97) | 63 (34-85) | 65 (35-89) | 64 (39-97) | .6 |
| Sex (N = 272) | |||||
| Male | 179 (66%) | 59 (61%) | 86 (69%) | 34 (67%) | .5 |
| Female | 93 (34%) | 37 (39%) | 39 (31%) | 17 (33%) | — |
| Male/female ratio | 1.9:1 | 1.6:1 | 2.2:1 | 2.0:1 | — |
| Stage (N = 251) | |||||
| AO | 121 (48%) | 48 (55%) | 54 (45%) | 19 (44%) | .1 |
| A | 67 (27%) | 25 (28%) | 31 (26%) | 11 (26%) | — |
| B | 51 (20%) | 14 (16%) | 25 (21%) | 12 (28%) | — |
| C | 12 (5%) | 1 (1%) | 10 (8%) | 1 (2%) | — |
| Genomic aberrations (N = 152) | |||||
| Deletion 13q14 | 50 | 15 | 25 | 10 | — |
| Trisomy 12 | 20 | 6 | 12 | 2 | — |
| Deletion 11q23 | 18 | 5 | 9 | 4 | — |
| Deletion 17p13 | 1 | 1 | 0 | 0 | — |
| t(14;18)/IGH-BCL2 fusion * | 5 | 2 | 1 | 1 | — |
| IGHV mutational status (N = 225) | |||||
| Mutated (<98% homology to germline) | 155 (69%) | 54 (71%) | 76 (70%) | 25 (63%) | .4 |
| Unmutated | 66 (29%) | 19 (25%) | 32 (29%) | 15 (37%) | — |
| Mean WCC at diagnosis (N = 249), (range) | 41 (4.3-554) | 37.9 (5.5-234) | 51.4 (4.5-554) | 33.8 (4.3-254) | .3 |
| Treatment status (N = 250) | |||||
| Treated | 98 (39%) | 35 (40%) | 46 (38%) | 17 (40%) | .9 |
| Untreated | 152 (61%) | 52 (60%) | 74 (62%) | 26 (60%) | — |
| Mean time from diagnosis to first treatment (N = 98), mo | 28.5 | 28 | 25.6 | 32 | .3 |
| Survival (N = 258) | |||||
| Dead | 34 (13%) | 14 (16%) | 16 (13%) | 4 (9%) | .5 |
| Alive | 224 (87%) | 76 (84%) | 106 (87%) | 42 (91%) | — |
| BCL2 expression (N = 100) | |||||
| High (BCL2:actin ratio/SC-1>0.48) | 80 (80%) | 31 (89%) | 32 (73%) | 17 (81%) | .7 |
| Low (BCL2:actin ratio/SC-1<0.48) | 20 (20%) | 4 (11%) | 12 (27%) | 4 (19%) | — |
No significant association of the BCL2 promoter SNP was seen in this series with any variable assessed.
WCC indicates white cell count; and —, not applicable.